(Q41368098)

30 September 2017

title

Therapy of chronic type B hepatitis with adenine arabinoside and adenine arabinoside monophosphate (English)

1 reference

30 September 2017

Hoofnagle JH

1

1 reference

30 September 2017

publication date

1 January 1986

1 reference

30 September 2017

published in

Journal of Hepatology

1 reference

30 September 2017

volume

3 Suppl 2

1 reference

30 September 2017

page(s)

S73-80

1 reference

Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Effect of Vidarabine on Chronic Hepatitis B Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Adenine arabinoside 5′-monophosphate treatment of chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Treatment of chronic type B hepatitis with multiple ten-day courses of adenine arabinoside monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Toxicity of vidarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980103-9

7 January 2021

10.1016/S0168-8278(86)80103-9

Identifiers

DOI

1 reference

30 September 2017

1 reference